Vicore Pharma announces systemic sclerosis as the second indication for VP01
“We have decided to explore vascular mechanisms in diffuse systemic sclerosis as a complement to the antifibrotic effects investigated in IPF. The strong upregulation of AT2R in diffuse systemic sclerosis makes VP01 (C21) a distinctive target for this disease and presents an exciting opportunity for Vicore and its lead program, VP01”, says Carl-Johan Dalsgaard, CEO of Vicore Pharma.
Diffuse systemic sclerosis is a rare chronic severe autoimmune disease affecting skin as well as inner organs such as the lung. There is no cure for the disease and severe cases are treated with potent immunomodulatory drugs or autologous stem cell transplantation, with remaining challenges and high unmet need. It has been estimated that between 150-400 individuals per million have systemic sclerosis and its prevalence varies depending on factors such as geography. It is estimated that 20% of the systemic sclerosis patient population has the severe diffuse form. Systemic sclerosis is 3-4 times more common in women than men.
For further information, please contact:
Carl-Johan Dalsgaard, CEO tel: +46 (0)70 975 98 63, firstname.lastname@example.org
This information is information that Vicore Pharma Holding AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication through the agency of the contact person set out above, at 08:00 CET on April 23, 2019